Godrej Agrovet Limited — PPTs, 05-08-2026: Investor Presentation

Godrej Agrovet's Board has approved the financial results for the quarter.

1. **Business Performance:** The company posted a 10% YoY rise in consolidated sales to ₹2,852 Cr for Q1FY27. However, profit after tax (PAT) dipped 15% to ₹126 Cr, impacted by transient cost headwinds. Animal Nutrition (India) and Oil Palm businesses showed strong revenue and profit growth. Crop Care saw a revenue decline due to delayed monsoons, while Creamline Dairy and Godrej Foods faced margin pressure from high input costs. Astec LifeSciences improved significantly, nearing EBITDA break-even.

2. **Growth Drivers or Strategy:** Godrej Agrovet is undergoing a "structural reset" to shift from commodity-led thinking to a customer-facing approach. The strategy focuses on selective capital allocation towards high-margin businesses like Cattle Feed, Oil Palm, Crop Care, and branded GFL products, with a planned capex of ₹300-350 Cr/year. The company is also sharply focused on improving Net Working Capital efficiency, which saw a healthy improvement this quarter.

3. **Recent Developments:** New product launches are gaining traction. Crop Care's Ashitaka (Maize herbicide) volumes tripled, Takai (Paddy insecticide) expanded to five new crops, and Ghassnash (Soybean herbicide) was launched. Godrej Foods saw new product developments contribute ~20% to B2C revenue, boosting market share in frozen chicken and momos. Creamline Dairy's value-added products like ₹20 flavored milk and ₹99 protein paneer are also scaling well.

4. **Key Financial Metrics:** Consolidated Sales at ₹2,852 Cr (+10% YoY). Consolidated PAT at ₹126 Cr (-15% YoY). Average Net Working Capital days improved from 31 to 21 YoY, and in value terms from ₹878 Cr to ₹665 Cr.

5. **Management Commentary / Outlook:** Management is focusing on calibrated pricing, procurement efficiencies, and cost optimization to mitigate near-term pressures in Dairy and Foods segments. The innovation-led growth strategy in Crop Care is showing early success, and Astec LifeSciences is positioned for sustained profitability and growth following its operational turnaround.